| Authors: |
Safonov A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Lee M; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Brown DN; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Boscolo Bielo L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Translational Oncology Partnership Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mehine M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bandlamudi C; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., O'Leary B; Royal Marsden Hospital and Institute of Cancer Research, London, UK., Shao H; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vicente L; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Muldoon D; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhu A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ros S; AstraZeneca, Cambridge, UK., Marra A; Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy., Selenica P; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bieche I; Department of Genetics, Institut Curie, Paris, France., Wubbenhorst B; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Ferraro E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy., Courtois L; Department of Genetics, Institut Curie, Paris, France., El Botty R; Laboratory of Preclinical Investigation, Institut Curie, Paris, France., Ahmed M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Moiso E; Translational Oncology Partnership Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., An JA; Translational Oncology Partnership Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Donoghue MTA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Will M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pareja F; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Nizialek E; AstraZeneca, Cambridge, UK., Lukashchuk N; AstraZeneca, Cambridge, UK., Sofianopoulou E; AstraZeneca, Cambridge, UK., Liu Y; Pfizer, New York, NY, USA., Huang X; Pfizer, New York, NY, USA., Chappey C; Pfizer, New York, NY, USA., Staniszewska AD; AstraZeneca, Cambridge, UK., Ross D; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mandelker D; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Schultz N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Berger MF; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Scaltriti M; AstraZeneca, Gaithersburg, MD, USA., Reis-Filho JS; AstraZeneca, Gaithersburg, MD, USA., Li BT; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; AstraZeneca, Gaithersburg, MD, USA., Offit K; Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Norton L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shen R; Pfizer, New York, NY, USA., Maxwell KN; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Couch F; Experimental Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA., Domchek SM; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Marangoni E; Department of Genetics, Institut Curie, Paris, France., Shah S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Albertella MR; AstraZeneca, Cambridge, UK., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; AstraZeneca, Cambridge, UK., Weigelt B; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Solit DB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Nathanson KL; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Basser Center for BRCA, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Robson ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.; Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Turner NC; Royal Marsden Hospital and Institute of Cancer Research, London, UK., Chandarlapaty S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org.; Weill Cornell Medical College, New York, NY, USA. chandars@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. chandars@mskcc.org., Razavi P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org.; Weill Cornell Medical College, New York, NY, USA. razavip@mskcc.org.; Translational Oncology Partnership Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. razavip@mskcc.org. |
